A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD: August 2022

It's been a busy three months here at Oncology Data Advisor (ODA) since I last banged out an "Editor's Notes." One of the highlights was ODA's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting. Many researchers spoke on camera with us about the work they were presenting at the meeting, and visibility for the website increased tremendously. It was a rousing success. I remain incredibly proud of all the hard work our staff does every day to bring the cutting edge of clini...

A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD: May 2022

From my perch atop the masthead at Oncology Data Advisor, I am awed by the dozens of oncology professionals who give freely of their time and expertise to inform our readership of the latest in their respective areas. Their efforts are what make ODA a premier online resource for all things in this ever-evolving field. My heartfelt thanks go to these wonderful colleagues without whom we would cease to be a publication. In this month's Editor's Letter, I would like to highlight a few of the outsta...

A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD

It is my pleasure to assume the post of Editor in Chief of Oncology Data Advisor for 2022. One of the perks of this role is the opportunity to speak directly to you, the readership, about everything we are up to here. Not only do we strive to give you trenchant summaries of the latest and most relevant oncology treatment breakthroughs in print, podcast, and video formats, but we also aim to give you insights into where our experts believe oncology is headed and what hurdles need to be cleared be...

Copyright © 2022 Oncology Data Advisor. All rights reserved.